Jennifer Raab

Special Counsel
Full contact info

Experience

Neumora Therapeutics – $250.1 Million IPO

September 15, 2023

Cooley advised the underwriters on the $250.1 million initial public offering of Neumora Therapeutics, a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed.

Read more

Related contacts

Charlie Kim
Partner, San Diego
Kristin VanderPas
Partner, San Francisco
David Peinsipp
Partner, San Francisco
Denny Won
Partner, San Francisco
Grady Chang
Associate, Los Angeles Santa Monica
Madison (JJ) Meng
Associate, San Francisco
Kyle Huh
Associate, Palo Alto
Peter A. Haddad
Associate, San Diego
Heidi Ausman
Senior Paralegal, San Diego
Lila Hope
Partner, Palo Alto
Natasha Leskovsek
Of Counsel, Washington DC
Mika Reiner Mayer
Partner, Palo Alto
Barbara Mirza
Partner, Los Angeles Santa Monica
Phil Mitchell
Partner, New York
Jennifer Raab
Special Counsel, Palo Alto
Madhuri Roy
Partner, Palo Alto
Erica Russell
Associate, San Francisco
Randy Sabett
Special Counsel, Washington DC
Jennifer Shanley
Special Counsel, New York
Karen Tsai
Special Counsel, Washington DC
Francis Wheeler
Partner, Colorado
Mark Windfeld-Hansen
Senior Counsel, Palo Alto

Related Practices & Industries

Lulu’s – $92 Million IPO

November 17, 2021

Cooley advised the underwriters on fashion brand Lulu’s $92 million initial public offering of 5,750,000 shares of common stock, which now trade on the Nasdaq Global Market under the symbol LVLU. Lawyers David Peinsipp, Kristin VanderPas and Denny Won led the Cooley team advising the underwriters.

Read more

Related contacts

David Peinsipp
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
Denny Won
Partner, San Francisco
Valerie Sapozhnikova
Associate, Los Angeles Downtown
Marjorie Roesser
Associate, San Francisco
Lila Hope
Partner, Palo Alto
Jennifer Raab
Special Counsel, Palo Alto
Bobby Ghajar
Partner, Los Angeles Santa Monica
TJ Graham
Partner, Palo Alto
Caitlin Courtney
Associate, Palo Alto
Genevieve Lim Urban
Associate, Seattle
Barbara Mirza
Partner, Los Angeles Santa Monica
Randy Sabett
Special Counsel, Washington DC
Aaron Pomeroy
Partner, Colorado
Rick Jantz
Associate, Los Angeles Santa Monica
Rebecca Ross
Special Counsel, Washington DC
Francis Wheeler
Partner, Colorado
Drew Williamson
Partner, San Francisco

Related Practices & Industries

Zai Lab Enters License and Collaboration Agreement with Blueprint Medicines

November 10, 2021

Cooley advised Zai Lab on its exclusive collaboration and license agreement with Blueprint Medicines for the development and commercialization of BLU-945 and BLU-701 for the treatment of patients with epidermal growth factor receptor (EGFR) -driven non-small cell lung cancer (NSCLC) in Greater China, including mainland China, Hong Kong, Macau and Taiwan. 
 
Under the terms of the agreement, Blueprint Medicines will receive an upfront cash payment of $25 million and will be eligible to receive up to $590 million in potential development, regulatory and sales-based milestone payments, and tiered royalties on a product-by-product basis ranging from the low-teens to mid-teens on annual net sales of BLU-945 and BLU-701 in Greater China, subject to adjustment in specified circumstances. In addition, Zai Lab will be responsible for all the development costs for BLU-945 and BLU-701 occurring in Greater China and will receive the rights to develop and exclusively commercialize BLU-945 and BLU-701 in the region.
 
Lawyers Lila Hope and Jennifer Raab led the Cooley team advising Zai Lab.

 

Related contacts

Lila Hope
Partner, Palo Alto
Jennifer Raab
Special Counsel, Palo Alto

Related Practices & Industries

I-Mab Enters Global Strategic Partnership With AbbVie for Cancer Treatment

September 10, 2020

Cooley advised I-Mab on its global collaboration agreement with AbbVie for the development and commercialization of lemzoparlimab, one of I-Mab’s leading drug candidates, for the treatment of multiple cancers. Lawyers Lila Hope and Jennifer Raab led the Cooley team advising I-Mab on the agreement. 

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Jennifer Raab
Special Counsel, Palo Alto
Amanda Pacheco
Associate, Palo Alto
Jeffrey J. Tolin
Partner, New York
Rachel Thorn
Partner, New York
Andrew Epstein
Special Counsel, Seattle

Related Practices & Industries

Sangamo Announces Global Licensing Collaboration Agreement with Biogen

April 10, 2020

Cooley advised Sangamo Therapeutics, a clinical-stage biotechnology company, in its global licensing collaboration agreement with Biogen for the development and commercialization of gene regulation therapies for Alzheimer’s, Parkinson’s, neuromuscular and other neurological diseases.

Under the terms of the agreement, Sangamo will receive $225 million from the purchase by Biogen of newly issued Sangamo stock as well as an upfront license fee of $125 million. Additionally, Sangamo is eligible to earn up to $2.37 billion in other development, regulatory and commercial milestone payments, including up to $925 million in pre-approval milestone payments and up to $1.445 billion in first commercial sale and other sales-based milestone payments. Sangamo is also eligible to earn tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of products arising from the collaboration.

Related contacts

Marya Postner
Partner, Palo Alto
Jennifer Raab
Special Counsel, Palo Alto

Related Practices & Industries

View more

Memberships & affiliations

California Bar Association